公开(公告)号：US10792309B2

公开(公告)日：2020-10-06

申请号：US13966153

申请日：2013-08-13

Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Mi La Cho ,  Seok-Goo Cho ,  Jung-Yeon Lim ,  Hyun-Sil Park ,  Min-Jung Park

IPC: C07K14/715 ,  A61K35/28 ,  C12N5/0783 ,  C12N5/0775 ,  A61K31/21 ,  A61K39/00 ,  A61K35/17

Abstract: The present invention relates to a cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory T-cells as an active ingredient. By infusing mesenchymal stem cells and immunoregulatory T-cells, which are the cellular therapeutic agent of the present invention, into bone marrow transplant animals, rejection to the host is suppressed after the engraftment of the transplanted bone-marrow to thus obtain the effect of reducing graft-versus-host disease and immune disease. Moreover, the effect of such GVHD reduction is much greater than the one obtained when only mesenchymal stem cells are infused. Accordingly, the cell therapy composition of the present invention having the above-mentioned effects can be useful in the prevention or treatment of immune disease.

公开(公告)号：US20170239295A1

公开(公告)日：2017-08-24

申请号：US13966153

申请日：2013-08-13

Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Mi La Cho ,  Seok-Goo Cho ,  Jung-Yeon Lim ,  Hyun-Sil Park ,  Min-Jung Park

IPC: A61K35/28 ,  C12N5/0775 ,  C12N5/0783 ,  A61K35/17

Abstract: The present invention relates to a cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory T-cells as an active ingredient. By infusing mesenchymal stem cells and immunoregulatory T-cells, which are the cellular therapeutic agent of the present invention, into bone marrow transplant animals, rejection to the host is suppressed after the engraftment of the transplanted bone-marrow to thus obtain the effect of reducing graft-versus-host disease and immune disease. Moreover, the effect of such GVHD reduction is much greater than the one obtained when only mesenchymal stem cells are infused. Accordingly, the cell therapy composition of the present invention having the above-mentioned effects can be useful in the prevention or treatment of immune disease.

公开(公告)号：US20150238445A1

公开(公告)日：2015-08-27

申请号：US14428920

申请日：2013-09-06

Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Mi-La Cho ,  Seon-Yeong Lee ,  Min-Jung Park ,  Jae-Seon Lee ,  Eun-Ji Yang ,  Eun-Kyung Kim ,  Jun-Geol Ryu ,  Hye-Jin Son

IPC: A61K31/155

CPC classification number: A61K31/155

Abstract: The present invention relates to a composition for preventing or treating immune diseases through the suppression of B cell activity induced by metformin. More particularly, the present invention relates to a composition comprising a metformin compound or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating immune diseases, wherein the composition is characterized by suppression or reduction of B cell activity which is a cause of disease. The present invention can be valuable in the use thereof for various autoimmune diseases as an immunosuppressant which can prevent or treat immune diseases by suppressing or reducing B cell activity and Th17 cell activity, which are causes of disease, or by promoting or increasing regulatory T cell activity.

Abstract translation: 本发明涉及通过抑制二甲双胍诱导的B细胞活性来预防或治疗免疫疾病的组合物。 更具体地，本发明涉及包含二甲双胍化合物或其药学上可接受的盐作为预防或治疗免疫疾病的活性成分的组合物，其中所述组合物的特征在于抑制或降低作为疾病原因的B细胞活性 。 本发明在各种自身免疫性疾病中作为免疫抑制剂的用途是有价值的，该免疫抑制剂可以通过抑制或降低作为疾病原因的B细胞活性和Th17细胞活性或通过促进或增加调节性T细胞来预防或治疗免疫疾病 活动。